PFE vs PLX

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Protalix (PLX) continues to exhibit strong potential for 10x growth, building on its recent financial turnaround. The stellar Q1 2026 performance, with $18.3 million net income and $0.22 GAAP EPS (as noted in prior analysis and consistent with current P/E), substantially de-risks profitability concerns. The reaffirmed 2026 revenue guidance of $78–$83 million, backed by the $25 million Chiesi miles...